Navigation Links
Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Date:9/19/2007

WIXOM, Mich., Sept. 19 /PRNewswire-FirstCall/ -- Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end- stage-renal-disease market (ESRD), announced today that it has commenced enrollment in its Phase IIb dose-ranging study for Soluble Ferric Pyrophosphate (SFP), a physiological iron-maintenance therapy drug.

The Phase IIb dose-ranging study is a nine-month, controlled multi-center, double-blind study consisting of up to 130 patients at multiple dialysis centers in the United States. Patients will receive SFP during their normal three times/week dialysis regimen. The primary objectives of this study are to evaluate both safety and efficacy of SFP at varying dosage levels and to determine the optimal concentration of SFP that will maintain iron balance within the target hemoglobin range, in patients undergoing hemodialysis. Secondary endpoints include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session. Results of this Phase IIb study are expected by the end of 2008.

Robert L. Chioini, Chairman and CEO of Rockwell stated, "We are excited to initiate this important step in our clinical development plan for SFP, a key product in Rockwell's renal drug development pipeline. The completion of this study will enable us to initiate our planned Phase III pivotal study program for FDA market approval of SFP. Mr. Chioini also stated, "We have assembled a team of top-tier investigators who will be conducti
'/>"/>

SOURCE Rockwell Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the Morgan ... at 10:20 a.m. ET. The conference will be held ... New York City . About Abaxis ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014  Arena ... that the US Food and Drug Administration (FDA) has ... of pulmonary arterial hypertension. "The FDA ... clinical data submissions from sponsors to identify and designate ... help advance the evaluation and development of such products," ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... ARLINGTON HEIGHTS, Ill., Sept. 12 Even as,many ... available today,we are stopped by our rear reflection and ... study published in the October issue of Plastic and,Reconstructive ... Plastic Surgeons (ASPS), reveals a new back lift procedure ...
... Ala., Sept. 11 - Southern,Research Institute and ... from a study testing Naltrexone-derived,pyridomorphinan (SoRI-9409) will ... of,the journal Biological Psychiatry. The publication is ... suggests that a new compound that,causes selective ...
Cached Medicine Technology:Say 'Goodbye' to Back Fat Rolls 2Novel Compound Shows Promise for Treatment of Alcoholism 2Novel Compound Shows Promise for Treatment of Alcoholism 3Novel Compound Shows Promise for Treatment of Alcoholism 4
(Date:9/2/2014)... Healthcare professionals will be able to access ... available at the point of care following an agreement ... Comprehensive Cancer Network® (NCCN®). Information from NCCN will ... the content available from the clinical reference tool ... of 25 of the world's leading cancer centers devoted ...
(Date:9/2/2014)... from cancer surgery may be influenced by more ... Family conflicts and other non-medical problems may raise ... study has found. Addressing such quality-of-life issues before ... recoveries and save health care dollars, the research ... patients, and found that patients with a poor ...
(Date:9/2/2014)... the key to more youthful immune function might already ... in the Journal of Leukocyte Biology ... old mice had different responses to Mycobacterium tuberculosis ... were reversed by ibuprofen. , "Inflammation in old age ... Turner, Ph.D., a researcher involved in the work from ...
(Date:9/2/2014)... According to a new report by ... authority in medical device market research, the ... grow to over €2 billion in 2020. Growth ... number of procedures for the treatment of BPH, ... TURP devices, laser BPH devices, brachytherapy, urinary catheters, ...
(Date:9/2/2014)... New York (PRWEB) September 02, 2014 ... application of nanotechnology in diagnosing, treating and/or prevention ... are applied for treating cardiovascular, neurological, and oncology ... utilization of knowledge pertaining to various nanoparticles, their ... body., There still exists considerable scope for research ...
Breaking Medicine News(10 mins):Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices worldwide, today announced the company and,its employees ... million,through the Red Cross Society of China to ... Mr. Xu Hang and Mr. Li Xiting,Mindray,s co-chief ...
... alternative,medicine is a diverse group of health care ... traditional medicine. According to the U.S.,Department of Health ... and alternative medicine, which includes dietary supplements., ... of dietary supplements has grown considerably in the ...
... Hopkins undergraduates have designed and built a device to ... their beds and walk while remaining tethered to essential ... whether carefully supervised rehabilitation, as opposed to continuous sedation ... care patients. , Some clinicians believe that allowing ICU ...
... LONDON, May 29 More northern women feel bloating ... of them likely to,experience it at any one time, ... from the West Midlands and Yorkshire and Humberside fared ... experiencing the least,amount of bloated feelings. And 61% of ...
... youth smoking uptake greatly reduced if parents quit, LONDON, ... research shows that a child,s odds of daily smoking are,reduced ... continue,to smoke. And if both parents were smokers but quit, ... shows that mothers who,quit are less likely to have children ...
... The following is a,statement of Matthew L. Myers, ... Sheila Dixon and Baltimore City Health Department,Commissioner Dr. ... protect,the city,s children and health by proposing a ... The proliferation of individually sold cigars in ...
Cached Medicine News:Health News:Mindray Donates Cash and Equipment for Sichuan Earthquake Relief 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 5Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 6Health News:Students' device allows ICU patients to get back on their feet 2Health News:Students' device allows ICU patients to get back on their feet 3Health News:North South Divide Exists in UK Digestive Health 2Health News:North South Divide Exists in UK Digestive Health 3Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 2Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 3Health News:Parents: Quit Smoking and Your Children Are Less Likely to Smoke 4Health News:Baltimore's Proposed Ban on Sale of Single, Cheap Cigars Would Protect Kids and Health 2
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: